BioVie (NASDAQ:BIVI) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of BioVie (NASDAQ:BIVIFree Report) from a sell rating to a hold rating in a research note released on Sunday morning.

BioVie Stock Performance

NASDAQ BIVI opened at $1.90 on Friday. The stock has a 50-day moving average of $2.79 and a 200 day moving average of $7.26. BioVie has a one year low of $1.42 and a one year high of $75.00. The company has a market capitalization of $14.33 million, a price-to-earnings ratio of -0.02 and a beta of 0.66.

Hedge Funds Weigh In On BioVie

Several institutional investors have recently made changes to their positions in the business. Northern Trust Corp purchased a new position in BioVie during the fourth quarter valued at $34,000. Millennium Management LLC purchased a new stake in BioVie during the 4th quarter valued at approximately $245,000. Two Sigma Investments LP bought a new stake in BioVie in the 4th quarter valued at $57,000. Squarepoint Ops LLC bought a new stake in shares of BioVie in the fourth quarter worth about $28,000. Finally, NewEdge Advisors LLC increased its stake in BioVie by 283.7% in the 1st quarter. NewEdge Advisors LLC now owns 54,100 shares of the company’s stock worth $53,000 after acquiring an additional 40,000 shares during the last quarter. Institutional investors own 4.59% of the company’s stock.

BioVie Company Profile

(Get Free Report)

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.

Recommended Stories

Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.